Replies to post #276754 on Anavex Life Sciences Corp (AVXL)

[frrol]

You not have a "molecular biology understanding of its unique activation of S1". There is not much molecular biology evidence of it being a unique agonist. And when actually reading pre-clinical evidence, you see that it is in fact not unique in any discernible manner. Not yet. Hopefully it is unique - most importantly clinically. Which is very different, far more important, what we are trying to determine, and having some success so far.

[Foosfund]

Falconer, many thanks to you and others for the educational and informative comments on the science and impact of Anavex. You use the term Blarcamesine which is a foreign name to most. As I understand it, Blarcamesine is merely another name for 2-73 which is the same basic drug used for all AVXL studies with different packaging, etc. If 2-73 works on one, it should (or may) work on other CNS diseases. As I further understand it, 3-71 may be the new and improved version of 2-73 in early testing. Is my very basic understanding correct?